GSK Consumer: Looking for rhythm - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

GSK Consumer: Looking for rhythm

Oct 25, 2004

Performance summary
GSK Consumer Healthcare has reported 3% revenue growth during the third quarter ended September 2004. The company margins have improved significantly, thereby resulting in a 37% bottomline growth during the quarter. For the nine months ended September 2004, GSK has reported almost 8% revenue and around 7% bottomline growth.

(Rs m) 3QCY03 3QCY04 Change 9mCY03 9mCY04 Change
Net sales 2,281 2,350 3.0% 6,074 6,552 7.9%
Expenditure 1,986 1,928 -2.9% 5,048 5,446 7.9%
Operating Profit (EBDITA) 295 422 43.2% 1,026 1,106 7.8%
EBDITA margin (%) 12.9% 17.9%   16.9% 16.9%  
Other income 47 30 -36.1% 149 104 -30.2%
Interest (1) (3) 85.7% 5 -20 -476.9%
Depreciation 87 90 4.2% 269 268 -0.2%
Profit before Tax 257 364 42.0% 900 961 6.7%
Tax 87 138 58.4% 309 354 14.6%
Extraordinary income/(expense) (5) - - (22) - -
Profit after Tax 165 226 37.3% 569 607 6.6%
Net profit margin (%) 7.2% 9.6%   9.4% 9.3%  
No. of Shares (m) 45.4 45.4   45.4 45.4  
Diluted Earnings per share (Rs)* 14.5 19.9   16.7 17.8  
Price to earnings ratio (x)         14.1  
*(annualised), CY = Calendar Year            

What is the company’s business?
GSK Consumer dominates the Rs 13 bn Indian malted beverage market with a significant 65% share (volume terms). Its white beverage brand ‘Horlicks’ has led to the market growth of this sector in India and contributes around 80% to the company’s revenues. The company’s other brands include ‘Boost’, ‘Viva’ and ‘Maltova’. The company also earns 4-5% fees by marketing products for SmithKline Beecham Asia Pvt. Ltd, the parent’s 100% subsidiary. The subsidiary has well known brands like ‘Aquafresh’ in oral care segment, ‘Eno’ and ‘Crocin’ in OTC portfolio. It recently also took up marketing of ‘Iodex’ for GSK Pharma.

What has driven performance in 3QCY05?
Sales:  The company is still unable to find a rhythm in its revenue trend. It still seems to be struggling and is yet to stabilise. Its revenue trend has been very volatile over the last seven quarters (see chart). GSK Consumer has provided no indication of how the malted beverage segment is growing, but we believe that the segment growth has slowed from its earlier average of 10% plus rate over the past decade.

Operating margins:  One of the key reasons for the company reporting strong bottomline growth is the significant improvement in operating margins (up 5% YoY). This has come about as a result of a dip in advertising expenses as a percentage of sales, as well as its raw material costs. Also, the third quarter of last year was abnormally bad for the company, thus showing a higher base improvement this year. During the nine month period however, GSK's margins have remained stable.

Cost break-up
as a % of net sales 3QCY03 3QCY04 9mCY03 9mCY04
Stock 3.3% 1.5% -0.9% 1.0%
RM 34.5% 32.4% 36.0% 35.0%
Finished goods 1.2% 1.3% 1.0% 1.0%
Staff cost 10.0% 10.2% 10.5% 10.8%
Advertising 14.4% 12.5% 11.5% 11.0%
Other exps. 22.1% 23.0% 23.3% 23.2%
Patent and trademark 1.1% 0.5% 1.2% 0.5%
Def. Rev. exps. 0.5% 0.5% 0.6% 0.6%
Total 87.1% 82.1% 83.1% 83.1%

What to expect?
The management has declared a second interim dividend of Rs 3.7 per share, taking the total interim dividend for 2004 to Rs 7 per share. The stock is trading at Rs 252, reflecting a P/E of 14.1 times annualised 9mCY04 earnings and market cap to sales of 1.3x. GSK Consumer has no doubt made some progress in reversing the decline in topline over the past few quarters. However, market conditions continue to be difficult for this single product company. A full fledged recovery in the company's fortunes still seems some time away and therefore, we view the company cautiously.

Equitymaster requests your view! Post a comment on "GSK Consumer: Looking for rhythm". Click here!


More Views on News

GSK CONSUMER Announces Quarterly Results (3QFY20); Net Profit Up 25.1% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.1% YoY). Sales on the other hand came in at Rs 12 bn (up 3.8% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

GSK CONSUMER Announces Quarterly Results (2QFY20); Net Profit Up 25.3% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.3% YoY). Sales on the other hand came in at Rs 13 bn (up 5.7% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 15, 2020 (Close)


  • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks